Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
World game at war: why some European nations have threatened a World Cup boycott 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
TEANECK, N.J., May 07, 2018 -- The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on June 27, 2018, to stockholders of record at the close of business on June 6, 2018.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy and aquaculture. For further information, please visit www.pahc.com.
Contact:
Richard Johnson
Chief Financial Officer, Phibro Animal Health Corporation
+1 201-329-7300
[email protected]
